Portal de Periódicos da CAPES

Pregnancy outcomes of two patients exposed to ustekinumab in the first trimester

2014; Wiley; Volume: 55; Issue: 3 Linguagem: Inglês

10.1111/ajd.12214

1440-0960

Claire Sheeran, J. Nicolopoulos,

Pregnancy and Medication Impact

Australasian Journal of DermatologyVolume 55, Issue 3 p. 235-236 LETTER TO THE EDITOR Pregnancy outcomes of two patients exposed to ustekinumab in the first trimester Claire Sheeran, Claire Sheeran Dermatology Department, Royal Melbourne Hospital, Melbourne, Victoria, AustraliaSearch for more papers by this authorJennifer Nicolopoulos, Jennifer Nicolopoulos Dermatology Department, Royal Melbourne Hospital, Melbourne, Victoria, AustraliaSearch for more papers by this author Claire Sheeran, Claire Sheeran Dermatology Department, Royal Melbourne Hospital, Melbourne, Victoria, AustraliaSearch for more papers by this authorJennifer Nicolopoulos, Jennifer Nicolopoulos Dermatology Department, Royal Melbourne Hospital, Melbourne, Victoria, AustraliaSearch for more papers by this author First published: 12 August 2014 https://doi.org/10.1111/ajd.12214Citations: 36Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Leonardi CL, Kimball AB, Papp KA et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665–1674. 2Lebwohl M, Leonardi C, Griffiths CE et al. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. J. Am. Acad. Dermatol. 2012; 66: 731–741. 3Ledee-Bataille N, Dubanchet S, Coulomb-L'hermine A et al. A new role for natural killer cells, interleukin (IL)-12, and IL-18 in repeated implantation failure after in vitro fertilization. Fertil. Steril. 2004; 81: 59–65. 4Ledee-Bataille N, Bonnet-Chea K, Hosny G et al. Role of the endometrial tripod interleukin-18, -15, and -12 in inadequate uterine receptivity in patients with a history of repeated in vitro fertilization-embryo transfer failure. Fertil. Steril. 2005; 83: 598–605. 5van Mourik MS, Macklon NS, Heijnen CJ. Embryonic implantation: cytokines, adhesion molecules, and immune cells in establishing an implantation environment. J. Leukoc. Biol. 2009; 85: 4–19. 6Neta GI, von Ehrenstein OS, Goldman LR et al. Umbilical cord serum cytokine levels and risks of small-for-gestational-age and preterm birth. Am. J. Epidemiol. 2010; 171: 859–867. 7Uz YH, Murk W, Yetkin CE et al. Expression and role of interleukin-23 in human endometrium throughout the menstrual cycle and early pregnancy. J. Reprod. Immunol. 2010; 87: 21–27. Citing Literature Volume55, Issue3August 2014Pages 235-236 ReferencesRelatedInformation